Last ¥1,275 JPY
Change Today -40.00 / -3.04%
Volume 225.2K
4575 On Other Exchanges
Symbol
Exchange
Tokyo
As of 1:00 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

canbas co ltd (4575) Snapshot

Open
¥1,330
Previous Close
¥1,315
Day High
¥1,336
Day Low
¥1,215
52 Week High
01/14/15 - ¥2,959
52 Week Low
05/20/14 - ¥548.00
Market Cap
5.9B
Average Volume 10 Days
224.0K
EPS TTM
¥-99.58
Shares Outstanding
4.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CANBAS CO LTD (4575)

Related News

No related news articles were found.

canbas co ltd (4575) Related Businessweek News

No Related Businessweek News Found

canbas co ltd (4575) Details

CanBas Co., Ltd., a clinical-stage biopharmaceutical company, discovers and develops oncology drugs in Japan. The company’s lead product comprise CBP501, which has completed Phase II clinical trials for the treatment of late stage malignant pleural mesothelioma and non-small cell lung cancer; and has completed Phase I clinical trial for ovarian cancer. It also develops CBS9106 and CBS2400 preclinical stage products. The company was founded in 2000 and is based in Numazu, Japan.

12 Employees
Last Reported Date: 09/26/14
Founded in 2000

canbas co ltd (4575) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

canbas co ltd (4575) Key Developments

CanBas Co., Ltd. to Report Q2, 2015 Results on Feb 13, 2015

CanBas Co., Ltd. announced that they will report Q2, 2015 results on Feb 13, 2015

Stemline Therapeutics, Inc. Announces Exclusive License from Canbas Co., Ltd

Stemline Therapeutics Inc. announced that it has exclusively licensed from CanBas Co., Ltd. the rights to develop and commercialize a novel, oral small molecule reversible inhibitor of Exportin-1 (XPO1), a nuclear transport target also known as Chromosomal Maintenance Region-1 (CRM1). Stemline has acquired worldwide rights with the exception of Japan, Korea, Taiwan and China. Stemline will now refer to the compound as SL-801. Recent work has demonstrated that XPO1 is a clinically relevant target, and nuclear export inhibitors have emerged as a new approach in cancer treatment with activity in patients across multiple indications. Given that SL-801 is a novel reversible inhibitor of XPO1, Stemline believe it has the potential to offer a broad therapeutic window with dosing and scheduling flexibility. SL-801 has demonstrated preclinical anti-cancer activity, including efficacy and safety in animal models, across a wide array of solid and hematologic cancers. Stemline expects to file an Investigational New Drug (IND) application in 2015.

CanBas Co., Ltd. to Report Q1, 2015 Results on Nov 14, 2014

CanBas Co., Ltd. announced that they will report Q1, 2015 results on Nov 14, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4575:JP ¥1,275.00 JPY -40.00

4575 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4575.
View Industry Companies
 

Industry Analysis

4575

Industry Average

Valuation 4575 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 499.9x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 475.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANBAS CO LTD, please visit www.canbas.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.